pirenzepine has been researched along with Acute Disease in 70 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 9.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| "This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia." | 9.10 | Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 9.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 9.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Thirty adult patients with acute schizophrenia were included into six-week open-labelled, non-comparative trial of olanzapine with free dosing from 5 to 20 mg per day." | 9.09 | [The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia]. ( Beniashvili, AG; Morozova, MA; Zharkova, NB, 2000) |
| "Olanzapine is superior to placebo and ineffective-dose olanzapine in the maintenance therapy of schizophrenia." | 9.08 | Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, P; Wentley, AL, 1997) |
| "In a randomized, endoscopically controlled double-blind trial the effectiveness of a twice daily dose of the prostaglandin E2-analogue enprostil was compared with pirenzepine given to 97 ambulatory patients with duodenal ulcers." | 9.06 | [Enprostil in the acute treatment of duodenal ulcer: direct comparative study with pirenzepin]. ( Beckenbach, HP; Daake, H; Dammann, HG; Hüttemann, R; Kalek, S; Kühn, V; Müller, P; Rohner, HG; Simon, B, 1986) |
| "A double-blind clinical trial was carried out to evaluate the efficacy of pirenzepine (PZ) in acute pancreatitis (AP)." | 9.06 | Double-blind trial of pirenzepine in acute pancreatitis. ( Carbó, J; García-Buey, L; Moreno-Otero, R; Pajares, JM; Rodriguez, S, 1989) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 8.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| " Divalproex loading was as well tolerated or better tolerated than the other active treatments as measured by adverse events and changes in laboratory parameters." | 7.80 | The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. ( Baker, JD; Hirschfeld, RM; Sommerville, KW; Tracy, K; Wozniak, P, 2003) |
| "To report the first published case of olanzapine-induced acute pancreatitis." | 7.70 | Olanzapine-induced acute pancreatitis. ( Doucette, DE; Grenier, JP; Robertson, PS, 2000) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 6.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| "Pirenzepine is an atropine analogue approved to treat peptic ulcer disease in Europe that is devoid of central actions, which are mostly responsible for anti-muscarinic agents side effects." | 5.32 | Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. ( Adamson, PB; Foreman, RD; Pedretti, RF; Prete, G; Vanoli, E, 2003) |
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 5.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| "We aimed to compare clinical outcomes, health-related quality of life (HRQOL) and work status associated with olanzapine and haloperidol treatment in patients with bipolar disorder." | 5.10 | Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. ( Breier, A; Edgell, ET; Gandhi, G; Haro, JM; Namjoshi, MA; Shi, L; Tohen, M; Zhang, F, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia." | 5.10 | Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002) |
| "This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day) for manic or mixed episodes of bipolar disorder (N=251)." | 5.10 | Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. ( Altshuler, L; Baker, RW; Brown, E; Frye, M; Ketter, TA; Risser, RC; Schuh, LM; Suppes, T; Tohen, M; Zajecka, J; Zarate, CA, 2003) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 5.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 5.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "Thirty adult patients with acute schizophrenia were included into six-week open-labelled, non-comparative trial of olanzapine with free dosing from 5 to 20 mg per day." | 5.09 | [The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia]. ( Beniashvili, AG; Morozova, MA; Zharkova, NB, 2000) |
| " A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60)." | 5.09 | Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. ( Banov, MC; Breier, A; Francis, J; Grundy, SL; Jacobs, TG; Janicak, PG; McElroy, SL; Risser, R; Sanger, T; Tohen, M; Tollefson, GD; Toma, V; Zhang, F, 2000) |
| "Olanzapine is superior to placebo and ineffective-dose olanzapine in the maintenance therapy of schizophrenia." | 5.08 | Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, P; Wentley, AL, 1997) |
| "A double-blind clinical trial was carried out to evaluate the efficacy of pirenzepine (PZ) in acute pancreatitis (AP)." | 5.06 | Double-blind trial of pirenzepine in acute pancreatitis. ( Carbó, J; García-Buey, L; Moreno-Otero, R; Pajares, JM; Rodriguez, S, 1989) |
| "In a randomized, endoscopically controlled double-blind trial the effectiveness of a twice daily dose of the prostaglandin E2-analogue enprostil was compared with pirenzepine given to 97 ambulatory patients with duodenal ulcers." | 5.06 | [Enprostil in the acute treatment of duodenal ulcer: direct comparative study with pirenzepin]. ( Beckenbach, HP; Daake, H; Dammann, HG; Hüttemann, R; Kalek, S; Kühn, V; Müller, P; Rohner, HG; Simon, B, 1986) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 4.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| " The present article reviews important differences among antipsychotic drugs in the potential for, and occurrence of, serious adverse cardiac outcomes and suggests that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute significantly to a QTc prolongation that could result in potentially fatal ventricular arrhythmias." | 4.81 | Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. ( Beasley, CM; Czekalla, J; Kollack-Walker, S, 2001) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| " Divalproex loading was as well tolerated or better tolerated than the other active treatments as measured by adverse events and changes in laboratory parameters." | 3.80 | The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. ( Baker, JD; Hirschfeld, RM; Sommerville, KW; Tracy, K; Wozniak, P, 2003) |
| "The responses of seven consecutive adolescents (ages 12-17) with DSM-IV bipolar disorder, manic episode, treated with olanzapine were evaluated." | 3.70 | Olanzapine in the treatment of adolescent acute mania: a report of seven cases. ( Foster, KD; Keck, PE; McElroy, SL; Sorter, MT; Soutullo, CA, 1999) |
| "To report the first published case of olanzapine-induced acute pancreatitis." | 3.70 | Olanzapine-induced acute pancreatitis. ( Doucette, DE; Grenier, JP; Robertson, PS, 2000) |
| " Olanzapine is one of the atypical antipsychotics with efficacy for psychotic symptoms and a safer side-effect profile than typical antipsychotics." | 2.71 | The efficacy and safety of olanzapine for the treatment of geriatric psychosis. ( Hwang, JP; Lee, TW; Tsai, SJ; Yang, CH, 2003) |
| " The patients were treated with conventional antipsychotics for seven days after admission and were then randomised to the treatment arms with risperidone (4 mg/day) or with olanzapine (10 mg/day) at a fixed dosage in the first week and thereafter in flexible dosages for the remaining seven weeks." | 2.71 | Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. ( Kores Plesnicar, B; Krajnc, I; Tomori, M; Zalar, B, 2003) |
| "The design consisted of 2 successive, 6-week, double-blind periods and compared flexible dosing of olanzapine (5-20 mg/d, n = 234) with haloperidol (3-15 mg/d, n = 219)." | 2.71 | A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. ( Azorin, JM; Baker, RW; Breier, A; Emsley, RA; Evans, AR; Goldberg, JF; Gonzalez-Pinto Arrillaga, AM; Hardy-Bayle, MC; Lawson, WB; Namjoshi, MA; Risser, RC; Tohen, M; Vieta, E; Zhang, F, 2003) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 2.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| "A 3-week, randomized, double-blind trial compared flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day in divided doses) for the treatment of patients hospitalized for acute bipolar manic or mixed episodes." | 2.70 | Olanzapine versus divalproex in the treatment of acute mania. ( Altshuler, LL; Baker, RW; Breier, A; Gilmore, JA; Ketter, TA; Milton, DR; Risser, R; Suppes, T; Tohen, M; Tollefson, GA; Zarate, CA, 2002) |
| "Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol treated patients on overall measures of efficacy, including clinical response." | 2.69 | Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. ( Beasley, CM; Berg, PH; Lu, Y; Sanger, TM; Tollefson, GD; Tran, PV, 1999) |
| "Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class." | 2.40 | Efficacy of olanzapine: an overview of pivotal clinical trials. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| "Pirenzepine is an atropine analogue approved to treat peptic ulcer disease in Europe that is devoid of central actions, which are mostly responsible for anti-muscarinic agents side effects." | 1.32 | Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. ( Adamson, PB; Foreman, RD; Pedretti, RF; Prete, G; Vanoli, E, 2003) |
| "Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded." | 1.31 | Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. ( Gianfrancesco, FD; Grogg, AL; Mahmoud, RA; Nasrallah, HA; Wang, RH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.14) | 18.7374 |
| 1990's | 15 (21.43) | 18.2507 |
| 2000's | 50 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, L | 1 |
| Namjoshi, MA | 2 |
| Zhang, F | 3 |
| Gandhi, G | 1 |
| Edgell, ET | 1 |
| Tohen, M | 12 |
| Breier, A | 9 |
| Haro, JM | 1 |
| Carrasco, JL | 1 |
| Gutiérrez, M | 1 |
| Gómez, JC | 1 |
| Escobar, R | 1 |
| Alvarez, E | 1 |
| Cañas, F | 1 |
| Bobes, J | 1 |
| Gascón, J | 1 |
| Gibert, J | 1 |
| Gianfrancesco, FD | 1 |
| Grogg, AL | 1 |
| Mahmoud, RA | 1 |
| Wang, RH | 1 |
| Nasrallah, HA | 1 |
| Hwang, JP | 1 |
| Yang, CH | 1 |
| Lee, TW | 1 |
| Tsai, SJ | 1 |
| Baker, RW | 6 |
| Fawcett, J | 1 |
| Risser, RC | 4 |
| Schuh, LM | 2 |
| Brown, E | 2 |
| Stauffer, VL | 1 |
| Shao, L | 1 |
| Tollefson, GD | 8 |
| Kores Plesnicar, B | 1 |
| Zalar, B | 1 |
| Tomori, M | 1 |
| Krajnc, I | 1 |
| Frye, MA | 1 |
| Gitlin, MJ | 1 |
| Altshuler, LL | 2 |
| Maguire, GA | 1 |
| Phillips, G | 1 |
| Revicki, DA | 1 |
| Paramore, LC | 1 |
| Sommerville, KW | 2 |
| Swann, AC | 1 |
| Zajecka, JM | 1 |
| Pedretti, RF | 1 |
| Prete, G | 1 |
| Foreman, RD | 1 |
| Adamson, PB | 1 |
| Vanoli, E | 1 |
| Ketter, TA | 2 |
| Zarate, CA | 5 |
| Suppes, T | 3 |
| Frye, M | 1 |
| Altshuler, L | 1 |
| Zajecka, J | 1 |
| Kinon, BJ | 2 |
| Hill, AL | 2 |
| Liu, H | 1 |
| Kollack-Walker, S | 2 |
| Baldessarini, RJ | 1 |
| Hennen, J | 1 |
| Wilson, M | 1 |
| Calabrese, J | 1 |
| Chengappa, R | 1 |
| Keck, PE | 2 |
| McElroy, SL | 4 |
| Sachs, G | 1 |
| Vieta, E | 2 |
| Welge, JA | 1 |
| Yatham, LN | 3 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Carlson, CD | 1 |
| Cavazzoni, PA | 1 |
| Berg, PH | 3 |
| Wei, H | 1 |
| Beasley, CM | 8 |
| Kane, JM | 1 |
| Hirschfeld, RM | 1 |
| Baker, JD | 1 |
| Wozniak, P | 1 |
| Tracy, K | 1 |
| Grunze, H | 1 |
| Dittmann, S | 1 |
| Goldberg, JF | 1 |
| Gonzalez-Pinto Arrillaga, AM | 1 |
| Azorin, JM | 1 |
| Hardy-Bayle, MC | 1 |
| Lawson, WB | 1 |
| Emsley, RA | 1 |
| Evans, AR | 1 |
| Gostishchev, VK | 1 |
| Evseev, MA | 1 |
| Simon, B | 2 |
| Müller, P | 2 |
| Dammann, HG | 2 |
| Tryba, M | 1 |
| Huchzermeyer, H | 1 |
| Török, M | 1 |
| Zenz, M | 1 |
| Pahlow, J | 1 |
| Zimmermann, W | 1 |
| Frank, N | 1 |
| Philippi, M | 1 |
| Burkhard, B | 1 |
| Kalinin, AV | 1 |
| Loginov, AF | 1 |
| Antokhin, EA | 1 |
| Tran, PV | 3 |
| Dellva, MA | 2 |
| Tran, P | 1 |
| Wentley, AL | 1 |
| Hillard, JR | 1 |
| Leentjens, AF | 1 |
| Morrison, D | 1 |
| Clark, D | 1 |
| Goldfarb, E | 1 |
| McCoy, L | 1 |
| Landry, P | 1 |
| Cournoyer, J | 1 |
| Chambers, RA | 1 |
| Caracansi, A | 1 |
| Weiss, G | 1 |
| Sharif, ZA | 1 |
| Grundy, S | 2 |
| Sanger, TM | 3 |
| Lu, Y | 1 |
| Chengappa, KN | 3 |
| Daniel, DG | 1 |
| Petty, F | 1 |
| Centorrino, F | 1 |
| Wang, R | 1 |
| Grundy, SL | 2 |
| Greaney, MG | 1 |
| Jacobs, TG | 2 |
| David, SR | 3 |
| Toma, V | 2 |
| Soutullo, CA | 1 |
| Sorter, MT | 1 |
| Foster, KD | 1 |
| Morozova, MA | 1 |
| Zharkova, NB | 1 |
| Beniashvili, AG | 1 |
| Naber, D | 1 |
| Lal, S | 1 |
| Iskandar, H | 1 |
| Banov, MC | 1 |
| Janicak, PG | 1 |
| Sanger, T | 1 |
| Risser, R | 2 |
| Francis, J | 1 |
| Doucette, DE | 1 |
| Grenier, JP | 1 |
| Robertson, PS | 1 |
| Price, PL | 1 |
| Feifel, D | 1 |
| Ghaemi, SN | 1 |
| Karagianis, JL | 1 |
| Dawe, IC | 1 |
| Thakur, A | 1 |
| Bégin, S | 1 |
| Raskin, J | 1 |
| Roychowdhury, SM | 2 |
| Milton, DR | 2 |
| Jones, B | 2 |
| Taylor, CC | 2 |
| Meehan, K | 3 |
| Czekalla, J | 2 |
| Levine, J | 1 |
| Jacobs, T | 1 |
| Thase, ME | 1 |
| Kupfer, DJ | 2 |
| Mujica, R | 1 |
| Weiden, P | 1 |
| Wright, P | 2 |
| Birkett, M | 2 |
| Ferchland, I | 2 |
| Alaka, KJ | 1 |
| Saunders, JC | 1 |
| Krueger, J | 1 |
| Bradley, P | 1 |
| San, L | 1 |
| Bernardo, M | 1 |
| Reinstein, M | 1 |
| Kumar, R | 1 |
| Calabrese, JR | 1 |
| Bowden, CL | 1 |
| Sachs, GS | 1 |
| Keeter, EL | 1 |
| Feldman, PD | 2 |
| Brown, WA | 1 |
| Miller, DS | 1 |
| Lam, RW | 1 |
| Jagadheesan, K | 1 |
| de Haan, L | 1 |
| Beuk, N | 1 |
| Hoogenboom, B | 1 |
| Dingemans, P | 1 |
| Linszen, D | 1 |
| Meehan, KM | 1 |
| Wang, H | 1 |
| Nisivoccia, JR | 1 |
| Mintzer, JE | 1 |
| Beckett, LM | 1 |
| Mathias, S | 1 |
| Schaaf, LW | 1 |
| Sonntag, A | 1 |
| David, S | 1 |
| Sutton, V | 1 |
| Palmer, R | 1 |
| Dossenbach, M | 1 |
| Kiesler, G | 1 |
| Brook, S | 1 |
| Sheikh, RM | 1 |
| Ahmed, K | 1 |
| Gilmore, JA | 1 |
| Tollefson, GA | 1 |
| Moreno-Otero, R | 1 |
| Rodriguez, S | 1 |
| Carbó, J | 1 |
| García-Buey, L | 1 |
| Pajares, JM | 1 |
| Rohner, HG | 1 |
| Beckenbach, HP | 1 |
| Daake, H | 1 |
| Hüttemann, R | 1 |
| Kalek, S | 1 |
| Kühn, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277] | Phase 3 | 67 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | 2.14 |
| 2. IM Haloperidol Pus Lorazepam | 2.23 |
The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | -10.2 |
| 2. IM Haloperidol Plus Lorazepam | -9.9 |
15 reviews available for pirenzepine and Acute Disease
| Article | Year |
|---|---|
Treating acute mania.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Li | 2003 |
Optimal dosing of medications (in bipolar disorder).
Topics: Acute Disease; Affect; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Ch | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant | 2003 |
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dia | 2003 |
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].
Topics: Acute Disease; Algorithms; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiaze | 2003 |
Efficacy of olanzapine: an overview of pivotal clinical trials.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Male | 1997 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
Antipsychotic agents and bipolar disorder.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cl | 1998 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration | 1998 |
Common treatment goals of antipsychotics: acute treatment.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedu | 1998 |
Management of acute mania.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 1999 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep | 2000 |
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
Topics: Acute Disease; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Death, Sudden; Female; H | 2001 |
The role of novel antipsychotics in bipolar disorders.
Topics: Acute Disease; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Lithium; Ol | 2002 |
28 trials available for pirenzepine and Acute Disease
| Article | Year |
|---|---|
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; | 2002 |
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; | 2002 |
The efficacy and safety of olanzapine for the treatment of geriatric psychosis.
Topics: Acute Disease; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; | 2003 |
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-I | 2003 |
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.
Topics: Acute Disease; Adult; Ambulatory Care; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 2003 |
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Doub | 2003 |
Olanzapine versus placebo in acute mania: treatment responses in subgroups.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dou | 2003 |
Comparison of three antipsychotics in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Emergency Services, | 2003 |
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dia | 2003 |
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relatio | 2003 |
[Antisecretory and mucosa-protecting drugs in the acute care of peptic ulcer. Review of action principles, healing rates and side effects of approved ulcer drugs and drugs under clinical trial].
Topics: Acute Disease; Aluminum; Antacids; Anti-Ulcer Agents; Benzodiazepinones; Cimetidine; Clinical Trials | 1984 |
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; | 1997 |
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 1999 |
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepin | 1999 |
[The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia].
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rat | 2000 |
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dou | 2000 |
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double- | 2001 |
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric | 2001 |
Response to placebo among bipolar I disorder patients experiencing their first manic episode.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; | 2000 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent | 2001 |
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, | 2001 |
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Topics: Acute Disease; Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug | 2002 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Topics: Acute Disease; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Bl | 2002 |
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relatio | 2002 |
Olanzapine versus divalproex in the treatment of acute mania.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Doub | 2002 |
Double-blind trial of pirenzepine in acute pancreatitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amylases; Clinical Trials as Topic; Double-Blind Meth | 1989 |
[Enprostil in the acute treatment of duodenal ulcer: direct comparative study with pirenzepin].
Topics: Acute Disease; Adult; Anti-Ulcer Agents; Benzodiazepinones; Clinical Trials as Topic; Double-Blind M | 1986 |
28 other studies available for pirenzepine and Acute Disease
| Article | Year |
|---|---|
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Confidence Inte | 2002 |
Acute dysphoric mania: treatment response to olanzapine versus placebo.
Topics: Acute Disease; Affect; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; | 2003 |
Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Atenolol; Dogs; Dose-Response Relationship, Dru | 2003 |
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middl | 2003 |
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical T | 2003 |
[Long-term therapy with intuition].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical T | 2003 |
[Antisecretory therapy as a component of hemostasis in acute gastroduodenal ulcer bleedings].
Topics: Acute Disease; Anti-Ulcer Agents; Famotidine; Gastrointestinal Agents; Histamine H2 Antagonists; Hum | 2005 |
Single-drug and combined medication with cimetidine, antacids and pirenzepine in the prophylaxis of acute upper gastrointestinal bleeding.
Topics: Acute Disease; Antacids; Benzodiazepinones; Cimetidine; Drug Therapy, Combination; Gastrointestinal | 1983 |
[Duodenal ulcer in the aged. Diagnosis, therapy and disease course].
Topics: Acute Disease; Aged; Benzodiazepinones; Cimetidine; Duodenal Ulcer; Female; Humans; Male; Piperazine | 1981 |
[The possibilities of using gastrotsepin in treating digestive organ diseases].
Topics: Acute Disease; Adult; Antacids; Anti-Ulcer Agents; Chronic Disease; Digestive System Diseases; Drug | 1993 |
[Acute dystonia].
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dystonia; Female; Humans; Olanzapine; P | 1998 |
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Humans; Male; Obsessive-Co | 1998 |
Acute dystonia with olanzapine.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Dystonia; Female; Humans; Male; Middle Aged; O | 1998 |
Olanzapine overdose cause of acute extrapyramidal symptoms.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Drug Overdose; | 1998 |
Olanzapine in the treatment of adolescent acute mania: a report of seven cases.
Topics: Acute Disease; Adolescent; Benzodiazepines; Bipolar Disorder; Child; Female; Humans; Male; Olanzapin | 1999 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
St. John's wort and schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hypericum; Male; Olanza | 2000 |
Olanzapine-induced acute pancreatitis.
Topics: Acute Disease; Aged; Antipsychotic Agents; Benzodiazepines; Fatal Outcome; Female; Hemorrhage; Human | 2000 |
Olanzapine to treat the acute mania of bipolar disorder.
Topics: Acute Disease; Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disord | 2000 |
Rapid tranquilization with olanzapine in acute psychosis: a case series.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Administration Sc | 2001 |
Introduction: a new era in the pharmacotherapy of psychotic disorders.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Administration Schedule | 2001 |
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Se | 2001 |
Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam.
Topics: Acute Disease; Adult; Benzodiazepines; Clonazepam; Drug Therapy, Combination; Female; Humans; Inject | 2001 |
A correction.
Topics: Acute Disease; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Method; Hum | 2002 |
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepine | 2001 |
Olanzapine in acute bipolar mania.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Humans; | 2002 |
Eosinophilia associated with olanzapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Eosinophilia; Humans; Male; | 2002 |
The efficacy of olanzapine, as needed, to treat acute agitation in juveniles.
Topics: Acute Disease; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship | 2002 |